| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communication |
From the Laboratory of Epithelial Cancer Biology,*Head and Neck Service, the Department of Surgery,Department of Pathology,and Endocrinology Service, the Department of Medicine,¶Memorial Sloan-Kettering Cancer Center, New York, New York; and the Department of Pediatrics,Baylor College of Medicine, Houston, Texas
Several lines of evidence suggest that follicular cell-derived thyroid cancers represent a continuum of disease that progresses from the highly curable well-differentiated thyroid cancers to the universally fatal anaplastic cancers. However, the genetic mechanisms underlying thyroid cancer progression remain ill defined. We compared the molecular-cytogenetic profiles derived from comparative genomic hybridization (CGH) analysis of major histological variants of thyroid cancer to define genetic variables associated with progression. Overall, a sequential increase in chromosomal complexity was observed from well-differentiated papillary thyroid cancer to poorly differentiated and anaplastic carcinomas, both in terms of the presence of CGH detectable abnormalities (P = 0.003) and the median number of abnormalities per case (P < 0.001). The presence of multiple abnormalities common to all thyroid cancer variants, including gains of 5p15, 5q11–13, 19p, and 19q and loss of 8p, suggests that these tumors are derived from a common genetic pathway. Gains of 1p34–36, 6p21, 9q34, 17q25, and 20q and losses of 1p11-p31, 2q32–33, 4q11–13, 6q21, and 13q21–31 may represent secondary events in progression, as they were only detected in poorly differentiated and anaplastic carcinomas. Finally, recurrent gains at 3p13–14 and 11q13, and loss of 5q11–31 were unique to anaplastic carcinomas, suggesting they may be markers for anaplastic transformation. Our data suggests that the development of chromosomal instability underlies the progression to more aggressive phenotypes of thyroid cancer and sheds light on the possible genomic aberrations that may be selected for during this process.
This article has been cited by other articles:
 |
|
 |
|
  M. Volante, I. Rapa, M. Gandhi, G. Bussolati, D. Giachino, M. Papotti, and Y. E. Nikiforov RAS Mutations Are the Predominant Molecular Alteration in Poorly Differentiated Thyroid Carcinomas and Bear Prognostic Impact J. Clin. Endocrinol. Metab., December 1, 2009; 94(12): 4735 - 4741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Nucera, J. Eeckhoute, S. Finn, J. S. Carroll, A. H. Ligon, C. Priolo, G. Fadda, M. Toner, O. Sheils, M. Attard, et al. FOXA1 Is a Potential Oncogene in Anaplastic Thyroid Carcinoma Clin. Cancer Res., June 1, 2009; 15(11): 3680 - 3689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C Smallridge, L. A Marlow, and J. A Copland Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies Endocr. Relat. Cancer, March 1, 2009; 16(1): 17 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-J. Lee, A. Y M Au, T. Foukakis, M. Barbaro, N. Kiss, R. Clifton-Bligh, J. Staaf, A. Borg, L. Delbridge, B. G Robinson, et al. Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma Endocr. Relat. Cancer, September 1, 2008; 15(3): 801 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Arlot-Bonnemains, E. Baldini, B. Martin, J.-G. Delcros, M. Toller, F. Curcio, F. S Ambesi-Impiombato, M. D'Armiento, and S. Ulisse Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines Endocr. Relat. Cancer, June 1, 2008; 15(2): 559 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Salvatore, T. C. Nappi, P. Salerno, Y. Jiang, C. Garbi, C. Ugolini, P. Miccoli, F. Basolo, M. D. Castellone, A. M. Cirafici, et al. A Cell Proliferation and Chromosomal Instability Signature in Anaplastic Thyroid Carcinoma Cancer Res., November 1, 2007; 67(21): 10148 - 10158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Stoler, N. J. Nowak, S.-i. Matsui, S. M. Wiseman, N. Chen, S. S. Dutt, J. D. Bartos, T. R. Loree, N. R. Rigual, W. L. Hicks Jr, et al. Comparative Genomic Instabilities of Thyroid and Colon Cancers Arch Otolaryngol Head Neck Surg, May 1, 2007; 133(5): 457 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. W Baloch and V. A LiVolsi Our approach to follicular-patterned lesions of the thyroid J. Clin. Pathol., March 1, 2007; 60(3): 244 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Guida, G. Salvatore, P. Faviana, R. Giannini, G. Garcia-Rostan, L. Provitera, F. Basolo, A. Fusco, F. Carlomagno, and M. Santoro Mitogenic Effects of the Up-Regulation of Minichromosome Maintenance Proteins in Anaplastic Thyroid Carcinoma J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4703 - 4709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Baida, S. M. Farrington, P. Galofre, R. Marcos, and A. Velazquez Thyroid Cancer Susceptibility and THRA1 and BAT-40 Repeats Polymorphisms Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 638 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. E. Nikiforov Anaplastic Carcinoma of the Thyroid--Will Aurora B Light a Path for Treatment? J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1243 - 1245. [Full Text] [PDF]
|
|
|
|
 |
|
 V. B. Wreesmann, W. Shi, H. T. Thaler, A. Poluri, D. H. Kraus, D. Pfister, A. R. Shaha, J. P. Shah, P. H. Rao, and B. Singh Identification of Novel Prognosticators of Outcome in Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., October 1, 2004; 22(19): 3965 - 3972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. B. Wreesmann, E. M. Sieczka, N. D. Socci, M. Hezel, T. J. Belbin, G. Childs, S. G. Patel, K. N. Patel, G. Tallini, M. Prystowsky, et al. Genome-Wide Profiling of Papillary Thyroid Cancer Identifies MUC1 as an Independent Prognostic Marker Cancer Res., June 1, 2004; 64(11): 3780 - 3789. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
